Metabolic disorders and hepatitis: Insights from a Mendelian randomization study

• Published in: World journal of gastrointestinal surgery 2024-06, Vol.16 (6), p.1775-1790
• Main Authors: Liang, Ling-Bo, Liu, Xiang-Ping, Mao, Ting-Rui, Su, Qiao-Li
• Format: Article
• Language: English
• Subjects: Clinical and Translational Research
• ISSN: 1948-9366; 1948-9366
• DOI: 10.4240/wjgs.v16.i6.1775

Hepatitis is a systemic disease that often results in various comorbidities. Meta-bolic disorders, the most common comorbidities in clinical practice, were selected for this study. To investigate the causal relationship between comorbidities and hepatitis trea-tment outcomes. A total of 23583378 single nucleotide polymorphisms from 1248743 cases and related summaries of genome-wide association studies were obtained from online public databases. A two-sample Mendelian randomization (MR) was performed to investigate causality between exposure [type 2 diabetes mellitus (T2D), hyperlipidemia, and hypertension] and outcome (chronic hepatitis B or C in-fections). The data supported the causal relationship between comorbidities and hepatitis infections, which will affect the severity of hepatitis progression and will also provide a reference for clinical researchers. All three exposures showed a link with progression of both hepatitis B (T2D, = 0.851; hyperlipidemia, = 0.596; and hypertension, = 0.346) and hepatitis C (T2D, = 0.298; hyperlipidemia, = 0.141; and hypertension, = 0.035). The results of MR support a possible causal relationship between different ex-posures (T2D, hyperlipidemia, and hypertension) and chronic hepatitis progression; however, the potential mechanisms still need to be elucidated.